Figure 2.

Genomic differences between anti–PD-1–naïve and anti–PD-1–resistant R/M SCCHN cohorts. OncoPrint of genes more frequently mutated in the anti–PD-1–resistant cohort compared with the anti–PD-1–naïve cohort (for visualization purposes, a P value cutoff of P < 0.15 was selected), as well as a selection of genes that were previously shown (7,11,30) to be potentially involved in resistance mechanisms to anti–PD-L1 therapy (n = 153). For the patients subsequently treated with anti–PD-L1 therapy, clinical benefit was defined as a BOR of complete response, partial response, or stable disease lasting more than 6 months, whereas no clinical benefit was defined as a BOR of disease progression or stable disease lasting less than 6 months. NMD, nonsense-mediated decay.